Moody Aldrich Partners LLC Reduces Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Moody Aldrich Partners LLC decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 29.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 63,931 shares of the biopharmaceutical company's stock after selling 27,173 shares during the period. Moody Aldrich Partners LLC owned 0.06% of Intra-Cellular Therapies worth $5,340,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of ITCI. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the third quarter valued at approximately $32,000. GAMMA Investing LLC increased its position in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth about $74,000. Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies during the third quarter valued at about $97,000. Finally, Quarry LP grew its position in Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after buying an additional 1,300 shares during the period. Institutional investors own 92.33% of the company's stock.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Michael Halstead sold 22,869 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Price Performance

ITCI stock traded up $0.11 during trading on Wednesday, reaching $127.11. The company had a trading volume of 1,188,568 shares, compared to its average volume of 6,014,007. The business has a 50 day moving average of $94.97 and a 200 day moving average of $83.51. The company has a market cap of $13.48 billion, a P/E ratio of -146.11 and a beta of 0.70. Intra-Cellular Therapies, Inc. has a 52 week low of $62.78 and a 52 week high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. During the same quarter in the prior year, the firm earned ($0.25) earnings per share. The company's revenue for the quarter was up 39.0% compared to the same quarter last year. Research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ITCI. JPMorgan Chase & Co. raised their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a research note on Monday, November 4th. Morgan Stanley lifted their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Piper Sandler reaffirmed a "neutral" rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Needham & Company LLC reaffirmed a "hold" rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $102.15.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.